Antiviral activity of molnupiravir precursor NHC against SARS-CoV-2 Variants of Concern (VOCs) and its therapeutic window in a human lung cell model

Keywords: Molnupiravir, NHC, Anti-viral, ß-D-N4-hydroxicytidine, SARS-CoV-2

Running title: *In-vitro* activity of molnupiravir against SARS-CoV-2 Variants of Concern

Tessa Prince[1,2], I'ah Donovan-Banfield[1,2], Hannah Goldswain[1], Rebekah Penrice-Randal[1], Lance Turtle[1,2,3], Tom Fletcher[2,4], Saye Khoo[2,5], Julian A. Hiscox[1,2,6*]

[1]Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, UK.

[2]NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Liverpool, UK.

[3]Tropical and infectious Disease Unit, Liverpool University Hospitals NHS Foundation Trust.

[4]Liverpool School of Tropical Medicine, Liverpool, UK.

[5]Department of Pharmacology, University of Liverpool, Liverpool, UK.

[6]A*STAR Infectious Diseases Laboratories (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore.

[*]Corresponding author: julian.hiscox@liverpool.ac.uk Tel: +44 (0)151 795 0222

Synopsis

Background: The UK Medicines and Regulatory Healthcare Agency (MHRA) have recently licensed the anti-viral drug, molnupiravir, for use in patients with mild-moderate COVID-19 disease with one or more risk factors for serious illness. Treatment with anti-viral drugs is best initiated early to prevent progression to severe disease, although the therapeutic window for intervention has not yet been fully defined. **Objectives:** This study aimed to determine the activity of the molnupiravir (NHC) to different SARS-CoV-2 Variants of Concern (VoCs), and to establish the therapeutic window in human lung cell model. **Methods:** Dose response assays were performed in parallel to determine the IC50 (the concentration of drug required to inhibit virus titre by 50%) of NHC against different variants. Human ACE-2 A549 cells were treated with NHC at different time points either before, during or after infection with SARS-CoV-2. **Results**: Here we demonstrate that ß-D-N4-hydroxycytidine (NHC), the active metabolite of molnupiravir, has equivalent activity against four variants of SARS-CoV-2 in a human lung cell line ranging 0.04-0.16µM IC50. Furthermore, we demonstrate that *in-vitro* activity of the drug is reduced in cells exposed to drug 48 hours after infection. **Conclusions:** One of the main advantages of molnupiravir is that it can be administered orally, and thus given to patients in an out-patient setting. These results support giving the drug early on after diagnosis or even in prophylaxis for individuals with high risk of developing severe disease.

41 **Introduction**

42 SARS-CoV-2 emerged in China in late 2019 and has now caused more than 5 million deaths
43 across the world [1]. In common with other coronaviruses, SARS-CoV-2 genomic variants are
44 generated randomly through both single nucleotide polymorphisms and recombination
45 resulting in insertions and deletions. These changes can then be subject to selection pressure
46 in the host, including immune status and application of medical countermeasures. To date,
47 several Variants of Concern (VOCs) have emerged with apparently increased transmissibility
48 and reduced susceptibility to anti-viral antibodies. These VOCs include the Alpha variant
49 (B.1.17), the Beta variant (B.1.351) and the Delta variant (B.1.617.2). Most recently, the Delta
50 variant has predominated in the UK, and in much of the rest of the world.

51 While vaccination efforts have been largely successful in preventing severe disease, many
52 people worldwide remain either unable or unwilling to be vaccinated. However, vaccination
53 does not prevent household transmission [2]. Important groups of patients, such as those on
54 immunosuppressive therapies, mount sub optimal responses to vaccines [3]. Therefore,
55 effective treatments that are successful against multiple lineages of the virus are required.
56 Targeting unique (to the virus) but conserved regions across variants, affecting functions of
57 viral proteins such as the RNA dependent RNA polymerase (RdRp) (NSP12) is one such
58 approach.

59 Molnupiravir is an anti-viral pro-drug originally developed against influenza virus currently
60 undergoing clinical trials in humans for the treatment of COVID-19 [4,5]. Interim phase III results
61 suggested the drug reduced the risk of hospitalisation or death by 50% with efficacy
62 unaffected by the timing of symptom onset, underlying risk factors, or variant type (gamma,
63 delta, and mu) [6]. As a result, the MHRA in the UK has granted emergency use of the drug for

64 treatment of mild-moderate cases of COVID-19 in patients with at least one risk factor for
65 severe disease [7].
66 Treatment of SARS-CoV-2 infection in a ferret model of disease with molnupiravir resulted
67 in reduced upper respiratory tract viral load and blocked transmission between animals [8]. The
68 drug was also shown to be effective against SARS-CoV-2 infection in mice [9]. A combined anti-
69 viral effect with suboptimal doses of molnupiravir with favipiravir has also been reported in a
70 hamster model, demonstrating a 5-log drop in viral titre and a near complete halt in
71 transmission. However, in contrast, 24 hours post-infection the drop was 2.5 logs. Combined
72 treatment was found to cause increased C to U changes in comparison to single treatment [10].
73 Most of these studies have however used an early variant of the virus, a lineage A virus rather
74 than assessed the efficacy of the drug in the more recent VOCs.
75 Molnupiravir is a pro-drug and is converted enzymatically *in-vivo* to its active form, thereby
76 improving its absorption in the gastrointestinal tract and bioavailability. The active drug of
77 molnupiravir is known as NHC or ß-D-N4-hydroxycytidine and is used for *in-vitro* studies. NHC
78 has been tested against lineage-A SARS-CoV-2 in primary human lung epithelial cells and Calu-
79 3 cells and found to have an IC50 of approximately 0.08µM in Calu-3 cells and no cytotoxicity
80 after 48 hours [11]. Another study using Calu-3 cells found an IC50 after 24 hours of 0.4uM [12].
81 Two independent studies have demonstrated efficacy against the Alpha and Beta variants in
82 Vero E6 and Calu3 cells and shown to be equivalent to an ancestral strain [13,14]. In hACE2-A549
83 cells, the drug has an anti-viral effect at concentrations between 0.3 to 3µM [15]. As yet no
84 published *in-vitro* studies compare the drug efficacy at inhibiting viral replication to the Delta
85 variant of SARS-CoV-2. To investigate whether NHC is effective at inhibiting variants of SARS-
86 CoV-2 with equal efficiency, a human lung epithelial cell model (hACE2-A549 cells) was

87 infected at the same time as treatment with varying concentrations of the drug or treated at

88 different times.

Materials and Methods

Compound

NHC (Alsachim) was supplied as a 1mg powder and was resuspended in 1ml DMSO to provide a 4.07mM stock solution. This was diluted in viral maintenance media (DMEM containing 2% FBS and 0.05mg/ml gentamicin) for experiments using a range of concentrations.

Cell culture

Human ACE2-A549 (hACE2-A549), a lung epithelial cell line which overexpresses the ACE-2 receptor, were the kind gift of Oliver Schwartz [16]. These were used to test the drug. These were cultured in DMEM with 10% FBS and 0.05mg/ml gentamicin with the addition of 10µg/ml Blasticidin (Invitrogen). Only passage 3-10 cultures were used for experiments. Vero/hSLAM cells (PHE) were grown in DMEM with 10% FBS and 0.05mg/ml gentamicin (Merck) with the addition of 0.4mg/ml Geneticin (G418; Thermofisher) at 37°C/5% CO_2.

Viral Culture

Virus stocks were grown in Vero/hSLAM cells using DMEM containing 2% FBS, 0.05mg/ml gentamicin and 0.4mg/ml geneticin and harvested 72 hours post inoculation. Virus stocks were aliquoted and stored at -80°C. The titre of stocks (PFU/ml) was determined by plaque assay. RNA from viral stocks were sequenced by Oxford Nanopore long read length sequencing on flow cells run on GridION.

113 **Sequencing of viral stocks**

114 Sequencing libraries for amplicons generated by ARTIC were prepared following the 'PCR
115 tiling of SARS-CoV-2 virus with Native Barcoding' protocol provided by Oxford Nanopore
116 Technologies using LSK109 and EXP-NBD196. The artic-ncov2019 pipeline v1.2.1
117 (https://artic.network/ncov-2019/ncov2019-bioinformatics-sop.html) was used to filter
118 the passed fastq files produced by Nanopore sequencing with read lengths between 400
119 nt and 700 nt for ARTIC amplicons. This pipeline was then used to map the filtered reads
120 on the reference SARS-CoV-2 genome (MN908947.3) by minimap2 and assigned each read
121 alignment to a derived amplicon and excluded primer sequences based on the ARTIC V3
122 and V4 primer schemes in the bam files. Primer-trimmed bam files were further analysed
123 using DiversiTools (http://josephhughes.github.io/DiversiTools/) with the "-orfs" function
124 to generate the ratio of amino acid change in the reads and coverage at each site of protein
125 in comparison to the reference SARS-CoV-2 genome (MN908947.3). The amino acids with
126 highest ratio and coverage > 10 were used to assemble the consensus protein sequences.
127 Pangolin (https://pangolin.cog-uk.io/) was used to confirm lineages of each viral stock
128 used in experiments.

129

130 ***In-vitro* cytotoxicity of NHC**

131 Human ACE2-A549 cells were plated at 2 x 10^4 cells per well in a clear bottomed white 96
132 well plate. Twenty-four hours later the medium was replaced with media containing NHC
133 at different concentrations. At 72 hours post-exposure, cell viability was measured by
134 CellTiter-Glo assay (Promega) as per the manufacturer's instructions.

135

136

137 **Anti-viral activity of NHC against SARS-CoV-2 Variants of Concern (VoCs)**

138 Human ACE2-A549 cells were grown to confluency and infected at an MOI of 0.1 in either
139 DMEM with 2%FBS and 0.05mg/ml gentamicin, or in the same media containing 0.01µM,
140 0.1µM, 1µM or 10µM NHC by allowing virus to adsorb to cells in a volume of 100µl for one
141 hour at 37°C, and then topping up to 500µl with the relevant media afterwards. A mock
142 infected control and a DMSO control were included in each experiment and experiments
143 were repeated a minimum of 3 times. After 72 hours, supernatants were collected and
144 stored at -80°C until viral titre was determined by plaque assay. The inhibitory potency of
145 NHC measured as the absolute IC50 was defined as the concentration of drug that resulted
146 in a 50% reduction in the number of plaques compared to untreated controls.

147

148 **Pre-exposure and Post-exposure to NHC**

149 For pre-exposure experiments, media was removed from cells and replaced with media
150 containing NHC two hours prior to infection. This was then removed for infection, which
151 was performed as described above. For post-exposure experiments, infections were
152 performed in media as described above. At two, four, 24 or 48 hours post-infection, media
153 was removed from cells. The cells were washed twice with PBS, and the media replaced
154 with media containing 0µM, 0.01µM, 0.1µM, 1µM or 10µM NHC NHC. After 72 hours post-
155 infection, supernatants were collected and stored at -80°C until viral titre was determined
156 by plaque assay.

157

158 **Statistical analysis**

159 A one-way ANOVA was used to evaluate the in-vitro cytotoxicity data. The absolute IC50

160 values were calculated using GraphPad Prism 9, using a non-linear 4-parameter logistic

161 regression in a dose-response curve.

162

163 **Results**

164 In order to find the appropriate concentration range of NHC in hACE2-A549 cells, to
165 investigate the effect on viral biology, Cell-titer Glo Assay (Promega) were used to measure %
166 ATP production in cells. These were treated with DMSO or different concentrations of NHC
167 diluted in hACE2-A549 culture medium compared to mock untreated cells. DMSO, at the
168 highest concentration used (0.25%) had no effect on cells (p>0.05). There was a slight increase
169 in the ATP production in cells at the lowest concentration of drug, 0.01µM (p=0.02). The only
170 concentration of drug to inhibit the ATP production was 10µM (p>0.0001) (Figure 1).
171 Therefore, dose response assays to the drug could be conducted with concentrations of the
172 drug up to 10µM.



173

174 **Figure 1. In-vitro cytotoxicity of NHC to hACE2-A549 cells.** Cytotoxicity of different
175 concentrations (in µM) was measured using the Cell-titer Glo Assay to measure the
176 percentage ATP production in treated cells compared to mock treated cells (n=7). There was
177 no significant difference in % ATP production of cells compared to control cells in most
178 concentrations of NHC, except at 10uM (p<0.0001) and 0.1µM (p=0.02).

179 To determine the inhibitory activity of NHC against different VOCs and an ancestral B-lineage
180 virus, dose response assays were performed by infecting hACE2-A549 cells at an MOI of 0.1
181 in media alone and in media containing 0.01, 0.1, 1, and 10µM NHC. After 72 hours
182 incubation, cell supernatants were removed, and viral titres determined by plaque assay. The
183 IC50 (the concentration of drug required to inhibit virus titre by 50%) was determined using
184 non-linear regression with GraphPad Prism 9. The results demonstrated similar IC50 values
185 for each variant and the ancestral strain of between 0.04 and 0.16µM concentrations (Table
186 1) (Figure2).

Variant	**IC50 (µM)**	**95% CI**
Liverpool/REMRQ0001/2020 (B lineage)	0.111	0.04-0.54
Alpha (B.1.1.7)	0.104	0.05-0.02
Beta (B.1.351)	0.134	0.05-0.03
Delta (B.1.617.2)	0.103	0.06-0.16

187

188 **Table 1. IC50 values of NHC against variants in a hACE2-A549 human lung cell model.**
189 Inhibitory activity of NHC against an early variant of SARS-CoV-2
190 (Liverpool/REMRQ0001/2020) and Alpha (B.1.1.7), Beta (B.1.351) and Delta (B.1.617.2)
191 variants of concern (VOCs). A non-linear regression was used to calculate the IC50 for each
192 variant (n=4).



Figure 2. NHC is similarly active against both an early variant and VOCs. Inhibitory activity of NHC against an early variant of SARS-CoV-2 (Liverpool/REMRQ0001/2020) and Alpha (B.1.1.7), Beta (B.1.351) and Delta (B.1.617.2) variants of concern (VOCs). A non-linear regression was used to plot the dose response curves and calculate the IC50 for each variant (n=4).

To determine the effective treatment window, cells were both pre-treated with different concentrations of NHC two hours prior to infection and treated at two, four, 24- and 48-hours post-infection and compared to concurrent treatment/infection. Dose-response assays were performed on supernatants collected 72 hours post-infection. Viral titres remained similar if treatment was given prior to, or at the same time as infection and at time points of two, four- and 24-hours post-infection. However, if treatment was given at 48 hours post-infection, *in-vitro* activity of the drug was reduced for all variants tested (Figure 3).



208

209 **Figure 3. Effect of pre-treatment, concurrent treatment and treatment at two, four, 24 and**

210 **48 hours post-infection on inhibition of viral growth.** Dose response assays were performed

211 on supernatants collected 72 hours post-infection. Cells were either pre-treated with drug

212 prior to infection, treated at the same time as infection, or treated at different time points

213 post-infection. Treatment with drug inhibited growth of the virus to the same extent when

214 given prior to infection, concurrently, or two, four- or 24-hours post-infection. When

215 treatment was given 48 hours post-infection however, activity of the drug was reduced. A

216 non-linear regression was used to plot the dose response curves and calculate the IC50 for

217 each variant (n=3).

218 **Discussion**

219 These results support recent clinical trial data suggesting an inhibitory effect of
220 molnupiravir on SARS-CoV-2 [6]. Molnupiravir, as a nucleoside analogue, acts by mimicking
221 naturally occurring nucleosides to create error catastrophe during virus replication in the
222 host. Therefore, we would expect this compound to act against all variants of the virus in a
223 similar manner. This was tested in a cell culture system against four variants of SARS-CoV-2 (a
224 B-lineage virus compared to alpha, beta and delta variants). The data indicated a similar
225 pattern of growth inhibition for all four variants, suggestive of a common mechanism of
226 action. Furthermore, we have explored the therapeutic window in which the drug is most
227 active. We show that in infected cells the drug has reduced potency if given 48 hours post-
228 infection. This data supports the results of the MOVe-In trial, where use of Molnupiravir in
229 hospitalised patients was stopped prematurely since a statistically significant effect was
230 deemed unlikely [17] and reinforces the choice to license the drug for use in mild-moderate out-
231 patient cases.

232 However, *in-vitro* systems have several limitations in comparison to live models of
233 infection, so results should be interpreted with care, although the mechanism of action will
234 be intra-cellular. Use of molnupiravir in a Syrian hamster model infected with SARS-CoV-2
235 resulted in a drop in viral load and reduced lung pathology compared to controls [10,12].
236 Treatment 12 hours post-infection resulted in a protective effect [12] but not at 24 hours post-
237 infection. Further work is required to delineate the true treatment window of the drug in
238 humans with mild to moderate disease. Anti-viral drugs are best given early in infection to
239 reduce viral load. *In-vivo* ferret models have shown that severity is linked to the size of the
240 viral inoculum[18]. Therefore, molnupiravir likely acts to reduce disease by reducing viral load
241 in patients, and potentially subsequently reducing transmission.

242 One of the main benefits of molnupiravir as opposed to remdesivir is that it can be
243 administered orally. However, as was seen with the Influenza anti-viral, Tamiflu, resistance to
244 anti-virals can develop rapidly [19]. A thorough analysis of the potential of SARS-CoV-2 to
245 develop resistance is necessary, though it is likely that any adaptation for resistance will
246 correspond with a reduction in fitness as seen with remdesivir [20]. Use of molnupiravir would
247 likely be most beneficial if used in combination with another treatment, preferably targeting
248 a different part of the viral life cycle as has been used with success for HIV treatment. Finally,
249 molnupiravir has broad spectrum activity, shown to be effective against RSV, Influenza, and
250 seasonal coronaviruses in *in-vitro* models. Here we have shown that the *in-vitro* activity of
251 NHC is retained across a broad range of variants tested, suggesting that the drug can be
252 deployed widely, and clinical effectiveness is unlikely to be adversely impacted by these
253 different viral strains.
254

Acknowledgments Virus isolates used in this study were originally derived from samples gathered under the auspices of the ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC4C) and processed at the University of Liverpool. We would like to acknowledge all members of the consortium.

Funding: This work was funded by U.S. Food and Drug Administration Medical Countermeasures Initiative contract (75F40120C00085) awarded to JAH. The article reflects the views of the authors and does not represent the views or policies of the FDA. This work was also supported by the MRC (MR/W005611/1) G2P-UK: A national virology consortium to address phenotypic consequences of SARS-CoV-2 genomic variation (co-I JAH). JAH and LT are funded by the Centre of Excellence in Infectious Diseases Research (CEIDR) and the Alder Hey Charity. LT is supported by a Wellcome Trust fellowship [205228/Z/16/Z]. LT, TF and JAH are also supported by the National Institute for Health Research Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections (NIHR200907) at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health or Public Health England. For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.

Author contributions. Conceptualization: TP, TF, SK and JAH. Methodology: TP, ID-B, HG and RP-R. Validation: TP. Formal analysis: TP, ID-B, HG, RP-R and JAH. Investigation: TP. Resources: LT, SK and JAH. Data Curation: TP, ID-B, HG and RP-R. Writing – original draft: TP and JAH. Writing – Review and Editing: All authors. Visualisation: TP. Supervision: TF, SK and JAH. Project administration: JAH. Funding acquisition: TF, SK, LT and JAH.

278 **Transparency declaration.** The authors confirm they have no conflicts to declare.

279 **References**

280

281 1 Ritchie, H. *et al. Coronavirus Pandemic (COVID-19)*,

282 <https://ourworldindata.org/coronavirus> (2021).

283 2 Singanayagam, A. *et al.* Community transmission and viral load kinetics of the SARS-

284 CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK:

285 a prospective, longitudinal, cohort study. *The Lancet Infectious Diseases*,

286 doi:10.1016/S1473-3099(21)00648-4 (2021).

287 3 Kearns, P. *et al. Examining the Immunological Effects of COVID-19 Vaccination in*

288 *Patients with Conditions Potentially Leading to Diminished Immune Response*

289 *Capacity – The OCTAVE Trial.* , <Available at SSRN:

290 https://ssrn.com/abstract=3910058 or http://dx.doi.org/10.2139/ssrn.3910058>

291 (2021).

292 4 AGILE. *AGILE (Early Phase Platform Trial for COVID-19)*,

293 <https://clinicaltrials.gov/ct2/show/NCT04746183> (2021).

294 5 Khoo, S. H. *et al.* Optimal dose and safety of molnupiravir in patients with early

295 SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.

296 *Journal of Antimicrobial Chemotherapy* **76**, 3286-3295, doi:10.1093/jac/dkab318

297 (2021).

298 6 Mahase, E. Covid-19: Molnupiravir reduces risk of hospital admission or death by
299 50% in patients at risk, MSD reports. *BMJ* **375**, n2422, doi:10.1136/bmj.n2422
300 (2021).

301 7 Mahase, E. Covid-19: UK becomes first country to authorise antiviral molnupiravir.
302 *BMJ* **375**, n2697, doi:10.1136/bmj.n2697 (2021).

303 8 Cox, R. M., Wolf, J. D. & Plemper, R. K. Therapeutically administered ribonucleoside
304 analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. *Nat*
305 *Microbiol* **6**, 11-18, doi:10.1038/s41564-020-00835-2 (2021).

306 9 Wahl, A. *et al.* SARS-CoV-2 infection is effectively treated and prevented by EIDD-
307 2801. *Nature* **591**, 451-457, doi:10.1038/s41586-021-03312-w (2021).

308 10 Abdelnabi, R. *et al.* The combined treatment of Molnupiravir and Favipiravir results
309 in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
310 *EBioMedicine* **72**, 103595, doi:https://doi.org/10.1016/j.ebiom.2021.103595 (2021).

311 11 Sheahan, T. P. *et al.* An orally bioavailable broad-spectrum antiviral inhibits SARS-
312 CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
313 *Science Translational Medicine* **12**, eabb5883, doi:10.1126/scitranslmed.abb5883
314 (2020).

315 12 Rosenke, K. *et al.* Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the
316 Syrian hamster model. *Nature Communications* **12**, 2295, doi:10.1038/s41467-021-
317 22580-8 (2021).

318 13 Lee, J. *et al.* TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of
319 Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants
320 (B.1.1.7 and B.1.351). *Microbiol Spectr* **9**, e0047221, doi:10.1128/Spectrum.00472-21
321 (2021).

322 14 Stegmann, K. M. *et al.* N4-hydroxycytidine and inhibitors of dihydroorotate
323 dehydrogenase synergistically suppress SARS-CoV-2 replication. *bioRxiv*,
324 2021.2006.2028.450163, doi:10.1101/2021.06.28.450163 (2021).

325 15 Zhou, S. *et al.* β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal
326 Mutagenesis But Is Also Mutagenic To Mammalian Cells. *The Journal of Infectious*
327 *Diseases* **224**, 415-419, doi:10.1093/infdis/jiab247 (2021).

328 16 Buchrieser, J. *et al.* Syncytia formation by SARS-CoV-2-infected cells. *The EMBO*
329 *Journal* **39**, e106267, doi:https://doi.org/10.15252/embj.2020106267 (2020).

330 17 Merck. (2021).

331 18 Ryan, K. A. *et al.* Dose-dependent response to infection with SARS-CoV-2 in the ferret
332 model and evidence of protective immunity. *Nature Communications* **12**, 81,
333 doi:10.1038/s41467-020-20439-y (2021).

334 19 Moscona, A. Oseltamivir Resistance — Disabling Our Influenza Defenses. *New*
335 *England Journal of Medicine* **353**, 2633-2636, doi:10.1056/NEJMp058291 (2005).

336 20 Szemiel, A. M. *et al.* In vitro selection of Remdesivir resistance suggests evolutionary
337 predictability of SARS-CoV-2. *PLOS Pathogens* **17**, e1009929,
338 doi:10.1371/journal.ppat.1009929 (2021).